Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Double bonus or double trouble? Recruitment of married couples in the Age-Related Eye-Disease Study (AREDS)

Go back to Resources

Double bonus or double trouble? Recruitment of married couples in the Age-Related Eye-Disease Study (AREDS)

Authors:

Location:

Go back to Resources

Diminution of the Anti-PRP response to a combined DtaP/Hib vaccine by concurrent inactivated poliovirus vaccination

Go back to Resources

Diminution of the Anti-PRP response to a combined DtaP/Hib vaccine by concurrent inactivated poliovirus vaccination

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation Group

Go back to Resources

Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation Group

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Cyclosporine to tacrolimus: rejection, toxicity and cardiovascular risks

Go back to Resources

Cyclosporine to tacrolimus: rejection, toxicity and cardiovascular risks

Authors:

Location:

Go back to Resources

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

Go back to Resources

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eye drops

Go back to Resources

Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eye drops

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Comparison of the safety, vaccine virus shedding and immunogenicity of influenza virus vaccine, trivalent, types A and B, live-cold-adapted (LAIV) administered to HIV-infected and non-HIV-infected adults

Go back to Resources

Comparison of the safety, vaccine virus shedding and immunogenicity of influenza virus vaccine, trivalent, types A and B, live-cold-adapted (LAIV) administered to HIV-infected and non-HIV-infected adults

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Clinical trials resource. Treatment of advanced or recurrent squamous cell carcinoma of the head and neck

Go back to Resources

Clinical trials resource. Treatment of advanced or recurrent squamous cell carcinoma of the head and neck

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Clinical trials referral source. Current clinical trials of the anti- CD20 monoclonal antibody rituximab

Go back to Resources

Clinical trials referral source. Current clinical trials of the anti- CD20 monoclonal antibody rituximab

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Kidney Transplant Study Group; Tacrolimus versus Cyclosporine in Kidney Transplantation: Five year graft loss in patients with acute rejection and hypercholesterolemia

Go back to Resources

Kidney Transplant Study Group; Tacrolimus versus Cyclosporine in Kidney Transplantation: Five year graft loss in patients with acute rejection and hypercholesterolemia

Authors:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 124
  • Page 125
  • Page 126
  • Page 127
  • Current page 128
  • Page 129
  • Page 130
  • Page 131
  • Page 132
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • ISO Certification